Search

New MSK research supported the approval of a new treatment for ER-positive, HER2-negative advanced breast cancer; suggests a new strategy for overcoming resistance to Akt inhibitors in patients with PTEN-mutated prostate cancers; provides new understanding of B cell lymphomas that could lead to new treatments; examines using ChatGPT to help capture patient-reported outcomes; and developed the first customizable, scalable model for palliative care training for emergency departments.

After treatment for rectal cancer, Roxanne Joseph is back to enjoying an active life with her husband, Rory, and their two children. Recent research by MSK computational biologist Henry Walch is shedding light on why colorectal cancer has been more difficult to treat in many Black people.

Después de recibir tratamiento para el cáncer de recto, Roxanne Joseph ha vuelto a disfrutar de una vida activa junto a su marido, Rory, y sus dos hijos. Una investigación reciente realizada por Henry Walch, biólogo computacional del MSK, está arrojando luz sobre por qué el cáncer colorrectal ha sido más difícil de tratar en muchas personas de raza negra.

A new immunotherapy approach involves engineering CAR T cells to produce proteins that treat lymphoma.

Meet Tiffany Traina, a breast medical oncologist and the Vice Chair of the Department of Medicine at Memorial Sloan Kettering.

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval of new drugs and new indications in multiple myeloma clinical trials.

Meet Lisa DeAngelis, MSK's new Physician-in-Chief. She discusses her upbringing, her early career at MSK, and her top priorities as physician-in-chief.

Thank you to our donor community. Your commitment to supporting Memorial Sloan Kettering Cancer Center (MSK) is essential to advancing our mission.